|Brand Name:||Axosin IM|
|Therapeutic Class:||Third generation Cephalosporins|
|Manufacturer:||Ibn-Sina Pharmaceuticals Ltd.|
|Last Updated:||2020-11-21 18:15:00|
Axosin IM Injection contains Ceftriaxone. Axosin IM uses:
Axosin IM Injection is indicated for the treatment of the following infections when caused by susceptible organisms:
Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, E. coli, Enterobacter aerogenes, Proteus mirabilis, Serratia marcescens.
Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains), Moraxella catarrhalis (including beta-lactamase producing strains).
Skin and Skin Structure Infections caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, E. coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis, Peptostreptococcus species.
Urinary Tract Infections (complicated and uncomplicated) caused by E. coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Klebsiella pneumoniae.
Uncomplicated Gonorrhea (cervical, urethral, pharyngial and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae.
Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae.
Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, E. coli, Haemophilus influenzae, Klebsiella pneumoniae.
Bone and Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, E. coli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species.
Intra-abdominal Infections caused by E. coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species, Peptostreptococcus species.
Meningitis caused by Haemophilus influenzae, Neisseria meningitidis, Streptococcus pneumoniae. Axosin IM Injection has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis and E. coli.
Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of Axosin IM Injection may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated.
Axosin IM Injection contains Ceftriaxone 1 gm/vial. Axosin IM doses:
Generally, Axosin IM Injection should be taken once or equally devided twice a day for 4-14 days. Axosin IM Injection therapy should be continued for at least 2 days after the sign and symptoms of infection have disappeared.
The usual duration of therapy is 4 to 14 days; in complicated infections longer therapy may be required. No dosage adjustment is required for patients with renal or hepatic impairment.
Use the solution immediately after reconstitution of powder.
Generally Axosin IM Injection is well tolerated. However, few side effects including nausea, vomiting, diarrhea, dizziness and fever may occur.
Axosin IM Injection is a sterile, semisynthetic, broad-spectrum, 3rd generation cephalosporin antibiotic for intravenous or intramuscular administration. The bactericidal activity of Axosin IM Injection results from inhibition of cell wall synthesis. Axosin IM Injection has a high degree of stability in the presence of beta-lactamases both penicillinases and cephalosporinases of gram-negative and gram- positive bacteria.
Axosin IM Injection should be administered with caution to individuals with a history of gastrointestinal disease, particularly colitis.
May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level with probenecid.
Pregnancy: The safety of Axosin IM Injection in the treatment of infections during pregnancy has not been established. Axosin IM Injection should only be used during pregnancy if the likely benefit outweighs the potential risk to the fetus and/or the mother.
Lactation: Axosin IM Injection is excreted in breast milk at low concentrations. Therefore, caution should be exercised when Axosin IM Injection is administered to a nursing mother.
Axosin IM Injection should not be given to patients with a history of hypersensitivity to cephalosporin antibiotics. It is contraindicated in premature infants during the first 6 weeks of life. Its safety in human pregnancy has not been established. Axosin IM Injection is contraindicated in neonates if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium.
There is no specific antidote. Treatment of over dosage should be symptomatic.
Store below 25°C, protected from light & moisture. Use reconstituted solutions immediately.
Reconstituted solutions are stable for 6 hours at room temperature and for 24 hours at 2°-8°C. It should not be mixed in the same syringe with any drug other than 1% Lidocaine Hydrochloride injection BP (for IM injection only).
Axosin IM Injection price in Bangladesh 252.00